Was Jim Cramer Right About Pfizer Inc. (PFE)?

We recently published a list of Was Jim Cramer Right About These 12 Stocks? In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer discusses.

Back in 2024, on May 17, a caller asked about Pfizer Inc. (NYSE:PFE), which had struggled post-COVID. Cramer said the turnaround was underway and highlighted the stock’s dividend and pipeline, saying:

“I like Pfizer here. It’s making a big turn — people don’t even seem to be aware of it. I’ve been talking about it every day in the office. I keep saying, ‘Has anyone watched this turn in Pfizer?’ 5.8% yield. I always liked Seagen, which is the old Seattle Genetics — I think Dr. Bourla’s got it right. They have a lot of cash. Yes — Pfizer is a buy.”

Pfizer failed to deliver the turnaround Cramer expected, with shares down 21.06% since his buy recommendation.

A medical technician wearing protective gloves and a mask mixing a biopharmaceutical solution.

Pfizer Inc. (NYSE:PFE) is struggling to reassure investors despite a strong dividend and recent oncology-focused acquisitions. When asked about it again recently, Cramer stated that he remains a believer in the stock. Here’s what he said on May 12:

“You know, look, I think Pfizer, I think it can bottom here. I do believe, I still believe in the Seagen acquisition. I know I seem like, that I’m alone along with Dr. Bourla, but I think that there’s a lot of good stuff that they have, so I would say keep it here.”

Overall, PFE ranks 7th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PFE and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.